Information sheet: Best practice management of lung cancer
Information sheet: Best practice management of lung cancerSummaryThe best practice management of lung cancer course was originally developed by Cancer Australia and was transitioned to the eviQ Education portfolio in 2018. The course is currently undergoing a complete redevelopment in order to realign the content of the course with current best practice management principles in lung cancer.The purpose of the course is to provide health professionals with an understanding of the optimal care pathway for lung cancer and how to apply best practice management principles in the care of lung cancer patients.The target audience is health professionals working in the oncology setting or who may be involved in the care of people with lung cancer.Key project deliverablesDeliverableDescription (series sections)1 x eLearning series1. Prevention and screening2. Presentation, initial investigation and referral3. Diagnosis, staging and treatment planning4. Treatment and symptoms management5. Side effects and treatment related toxicities6. Follow-up7. End of life care8. SurvivorshipProject scopePresentation, initial investigation and referralSigns and symptoms Symptoms indicating an emergencyReferral MDTDiagnosis, staging and treatment planningEarly diagnosisAccess to curative treatmentStage at diagnosisStigma and nihilismSmoking cessation interventionsExercise interventionsTiming of referral to supportive care services, including early referral to palliative care and early intervention for symptom managementPsychological careRole of allied health professionals in the care of lung cancer patientsPre-habilitationClinical trialsTreatment and symptom managementTreatment options (patient suitability criteria)SurgerySystemic therapies – chemotherapy, targeted therapy, immunotherapyRadiation therapyPleural effusionPain reliefBrain metastasesFatigueBreathlessness and anxietyPharmacological managementNon-pharmacological management Side effects/treatment related complicationsacute side effectsimmune related adverse eventsFollow-upcumulative effects – maintenance therapylong term effects - radiotherapy and chemotherapyrapid re-entry into medical system – emergenciesrecurrence/retreatmentre-habilitationEnd of life careadvanced care planningcounselling death and dyinghonesty with prognosisSurvivorshipsurvivorship (consideration of late effects)Time framesThe project will run from May 2019 – May 2020 and will be released in 3 stages: Stage 1 (section 1-3), stage 2 (sections 4&5) and stage 3 (sections 6-8). The timelines for stage 1 have been included. Timelines for the remaining stages will be circulated as they become available. All committee members will receive approximately 6-8 weeks warning for when content will be circulated for review for the remaining modules. CommitteesAs per the eviQ Education Governance Framework all new development requires a comprehensive review of content by external stakeholders. The following committees will be overseeing this development. Clinical Advisory Committee (CAC)Provides clinical knowledge and experience to ensure the education resources are appropriate and fit for purpose while ensuring the content is correct, applicable and relevant. Responsibilities include review?and sign off of:content of modules and any associated resources,functionality and user experience of completed modules.Inclusion in the CAC requires:review time for each module as listed below (please note the estimated review times below are a guide only and there will be individual variations for reviewers).provision of feedback and comments on all content and associated documentation External Review Group (ERG)Members of the external review group provide clinical knowledge and experience and are asked to provide comments and feedback on the completed modules.Feedback is invited on some aspects of the content as well as the user experience; the aim of which is to ensure the modules are appropriate and fit for purpose while ensuring the content is correct, applicable and relevant.?The review is managed electronically and there are no requirements to attend any meetings.Estimated review time required (per module) Timelines for Stage 1The timelines detailed below are an estimation based upon current staff capacity. If any timelines are affected by changes to staff capacity, committee members will be notified without delay.ActivityStakeholder groupApproximate start and end datesContent ReviewCACMonday 03/06 - Sunday 23/06Review proposed content changesCACMonday 01/07 - Monday 07/07Module reviewCAC and ERGMonday 04/11 – Sunday 17/07Review proposed module changesCAC and ERGMonday 25/11 – Sunday 01/12Timelines for stage 2 will begin to become available by June 2019. It is currently estimated that content for stage 2 will be available for review in late July or early August. Committee members will receive regular updates.Want to be involved?If you have any questions or are interested in being part of any of the review groups please email us on Lisa.McLean@health..auExpressions of interest close on the 26th of May. ................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- attachment b
- abstract pharmaceutical benefits scheme pbs home
- registration status pbs
- the scottish government health directorates
- home faculty of health sciences queen s university
- journal of cancer
- future medicine ltd will provide fast track publication of
- australian public assessment report for nivolumab and
- template for electronic submission to acs journals
- home roy castle lung cancer foundation
Related searches
- knowledge management best practice models
- lung cancer high blood pressure
- project management best practice guide
- coding lung cancer in remission
- lung cancer in lymph nodes
- lung cancer brain mets survival
- stage 4 lung cancer spread to brain
- advances in lung cancer treatment
- immunotherapy for lung cancer 2019
- immunotherapy lung cancer latest news
- immunotherapy lung cancer survival rate
- immunotherapy for lung cancer prognosis